6533b829fe1ef96bd12899aa
RESEARCH PRODUCT
Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir® therapy: A case report
Simona DoniņaIneta NemiroElizabete PumpurePēteris AlbertsRaimundas MeskauskasAgnija RasaDana KigitovičaTatjana ZablockaEvija OlmaneSergejs IsajevsEva Dručkasubject
Oncologymedicine.medical_specialtyRigvirmedicine.medical_treatmentlcsh:MedicineCase ReportCase Reports030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineAdjuvant therapymelanomaMedicineRadical surgeryStage (cooking)ECHO-7 virusoncolytic viruslcsh:R5-920business.industryMelanomalcsh:RGeneral Medicinemedicine.diseaseOncolytic virusTolerability030220 oncology & carcinogenesisoncologyECHO‐7 virusbusinesslcsh:Medicine (General)AdjuvantRare diseaseuterine cervixdescription
Abstract Primary malignant melanoma of the uterine cervix is a rare disease with poor prognosis and high recurrence rate. We used Rigvir® as adjuvant therapy for a stage IVA patient. Tolerability, overall and progression‐free survival are good.
year | journal | country | edition | language |
---|---|---|---|---|
2020-05-22 | Clinical Case Reports |